iMDx is a molecular diagnostics company that develops decentralized testing solutions enabling hospitals, transplant centers, and clinical laboratories to perform diagnostic tests in-house rather than relying on centralized laboratory models. The company's flagship product, GraftAssure, measures donor-derived cell-free DNA to detect transplant rejection, offered through a laboratory-developed test with Medicare reimbursement, a research-use-only kit, and an in-vitro diagnostic kit in development. iMDx generates revenue through Medicare and private payer reimbursement for its transplant rejection tests, specimen collection and handling services, and laboratory services for biotechnology and life sciences companies, while also developing assays for oncology therapy selection and monitoring.